667, L.P.
CIK 1551139 · last filed 2026-06-29
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BGNE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
3RD FLOOR
NEW YORK, NY 10014
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VTVT | Director | — | $25.81 | — | $0 | 2 | 2026-06-29 |
| ACAD | Director | 39,487,463 | $19.74 | $779.48M | $630.00M | 3 | 2026-06-02 |
| ONC | Director | 730,643 | $370.87 | $270.97M | -$1.57M | 2 | 2026-05-27 |
| TCRX | Director | — | $0.19 | — | $0 | 3 | 2026-05-22 |
| INCY | Director | 28,482,491 | $113.31 | $3.23B | $0 | 11 | 2026-05-11 |
| REPL | Director | — | $12.47 | — | $0 | 1 | 2026-04-07 |
| DBVT | Director | — | $9.98 | — | $0 | 1 | 2026-01-14 |
| KOD | Director | 18,358,772 | $89.60 | $1.64B | $650.35M | 7 | 2025-12-19 |
| DNLI | Director | — | $18.66 | — | $0 | 1 | 2025-12-15 |
| MDGL | Director | 1,832,216 | $437.74 | $802.03M | $196.74M | 3 | 2025-08-20 |
| IMCR | Director | — | $31.28 | — | $0 | 1 | 2025-05-19 |
| IGM Biosciences, Inc. (IGMS) Delisted | Director | 355,142 | $1.27 | $451.0K | $0 | 9 | 2025-01-03 |
| BCYC | Director | 8,666,247 | $3.65 | $31.63M | $127.38M | 2 | 2024-12-17 |
| PRLD | Director | — | $3.70 | — | $0 | 2 | 2024-06-18 |
| BeOne Medicines Ltd. (BGNE) Delisted | Director | 126,096 | $184.71 | $23.29M | $3.77B | 2 | 2024-06-07 |
| NGNE | Director | 39,081 | $23.54 | $920.0K | $0 | 1 | 2023-12-20 |
| Talis Biomedical Corp (TLIS) Delisted | Director | — | $2.84 | — | $0 | 1 | 2023-06-13 |
| KNSA | Director | 132,566 | $72.98 | $9.67M | $0 | 2 | 2023-06-08 |
| Seagen Inc. (SGEN) Delisted | Director | 43,000,581 | $228.74 | $9.84B | $180.65M | 5 | 2023-06-02 |
| Neurogene Inc. (NLTX) Delisted | Director | — | $13.96 | — | $0 | 1 | 2021-05-13 |
| ZYME | Director | — | $28.37 | — | $0 | 1 | 2020-05-12 |
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 157,519 | — | — | -$482.48M | 10 | 2019-04-12 |
| Aceragen, Inc. (IDRA) Delisted | Director | 1,136 | $7.22 | $8.2K | $224.00M | 4 | 2018-06-21 |
| XOMA Royalty Corp (XOMA) Delisted | Director | 104,451 | $40.17 | $4.20M | -$59.06M | 1 | 2015-01-06 |
Recent Filings · Page 6 of 9
88 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-01-04 | INCY | Grant (A) | +5,028 | $0 | EDGAR |
| 2021-10-01 | KOD | Mixed | +1,421,490 | $49.98M | EDGAR |
| 2021-09-17 | KOD | Buy (P) | +191,028 | $18.03M | EDGAR |
| 2021-08-19 | KOD | Buy (P) | +686,376 | $60.06M | EDGAR |
| 2021-08-13 | KOD | Buy (P) | +616,638 | $53.76M | EDGAR |
| 2021-05-13 | Neurogene Inc. (NLTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-01-29 | IGM Biosciences, Inc. (IGMS) Delisted | Exer (M) | +134,520 | $3.85M | EDGAR |
| 2020-10-02 | INCY | Grant (A) | +3,804 | $0 | EDGAR |
| 2020-05-18 | — | Grant (A) | +55,884 | $0 | |
| 2020-05-12 | ZYME | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.